AstraZeneca and Daiichi Sankyo to evaluate Datroway with Summit's ivonescimab

What happened

On 2 October 2026, AstraZeneca and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types ^[1]. Endpoints News reported the same agreement, writing that "the biotech agreed to partner with AstraZeneca and Daiichi" ^[2].

The collaboration puts a marketed ADC next to Summit's ivonescimab. Datroway holds US approval for locally advanced or metastatic EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy, the indication carried on its FDA label ^[5]. AstraZeneca also reports a US approval in previously treated HR-positive, HER2-negative metastatic breast cancer ^[6].

Why it matters

Combining a TROP2 ADC with an immunotherapy is the next logical move for a drug developed and approved so far as a single agent ^[5][6]. For AstraZeneca and Daiichi Sankyo, pairing Datroway with Summit's ivonescimab extends the drug from monotherapy niches into combination settings where the commercial ceiling is higher, and it deepens the AstraZeneca-Summit relationship around a shared asset ^[1].

The breadth matters. "Multiple tumour types" signals the partners are not scoping this to one indication ^[1]. Datroway's existing footprint spans breast and lung, and its development has stumbled before: the EU marketing application in advanced nonsquamous NSCLC, based on the TROPION-Lung01 Phase III trial, was voluntarily withdrawn in December 2024 ^[8]. A combination strategy is one way to reopen indications where monotherapy data did not clear the bar.

Who is exposed

Any developer pairing a TROP2 agent with checkpoint blockade now faces a well-capitalised combination backed by an approved ADC and a large-pharma partner ^[1][5]. Because ivonescimab's mechanism and the specific tumour types enrolled are not established in public sources, Prognyx is not naming individual competitor programmes as exposed; the strategic signal is the combination itself.

What to watch next

The decision-relevant events are registration and design. Watch for an SEC filing from any of the three companies that would disclose financial terms, and for a Summit Therapeutics release confirming its side of the agreement ^[1][2].

The now-what

Three options are on the table for a competing team. One, assume the combination targets Datroway's established breast and lung franchises first and pressure-test your own sequencing there ^[5][6]. Two, treat "multiple tumour types" as reason to secure your own checkpoint or bispecific partner before the field consolidates ^[1]. Three, wait for the trial registration before reallocating, since the collaboration announcement alone does not yet tell you phase or indication ^[1].

What Prognyx could not verify

Prognyx could not confirm a ClinicalTrials.gov registration for the Datroway-plus-ivonescimab combination, so phase, tumour types and start date are not established. Prognyx could not confirm an SEC filing from Summit Therapeutics, AstraZeneca or Daiichi Sankyo disclosing deal terms. Ivonescimab's mechanism, sponsor and current trial status could not be confirmed from public sources as of this briefing. The prior AstraZeneca-Summit equity deal referenced in trade framing could not be confirmed, and Prognyx does not treat it as settled.

Verdict: medium threat to single-agent TROP2 and checkpoint strategies; the window to act runs until the combination trial registers, which will turn "multiple tumour types" into named indications and a phase.